Wolverine Trading, LLC Bristol Myers Squibb CO Call Options Transaction History

Wolverine Trading, LLC

$93.9 Billion
Q3 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $2.15 Million - $2.8 Million	54,100 Added 9.22%	640,700 $33.2 Million
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $7.36 Million - $9.69 Million	182,800 Added 45.27%	586,600 $24.4 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $8.8 Million - $9.98 Million	-183,400 Reduced 31.23%	403,800 $21.9 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $8.87 Million - $10.6 Million	183,000 Added 45.27%	587,200 $30.1 Million
Q3 2023 Nov 15, 2023	BUY	$57.89 - $64.73 $2.03 Million - $2.27 Million	35,000 Added 9.48%	404,200 $23.5 Million
Q2 2023 Aug 23, 2023	BUY	$63.71 - $70.74 $23.5 Million - $26.1 Million	369,200 New	369,200 $23.6 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $7,605 - $4.5 Million	58,500 Added 15.55%	434,600 $31.2 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $246,908 - $271,932	3,400 Added 0.91%	376,100 $29.4 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $10.8 Million - $12.9 Million	-175,500 Reduced 32.01%	372,700 $27.5 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $241,335 - $281,340	4,500 Added 0.83%	548,200 $34.3 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $4.43 Million - $5.19 Million	74,900 Added 15.98%	543,700 $33 Million
Q2 2021 Aug 06, 2021	BUY	$61.91 - $67.42 $7.78 Million - $8.47 Million	125,600 Added 36.6%	468,800 $31.1 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $4.32 Million - $4.86 Million	-72,800 Reduced 17.5%	343,200 $21.7 Million
Q4 2020 Feb 12, 2021	BUY	$57.74 - $65.43 $4.61 Million - $5.23 Million	79,900 Added 23.77%	416,000 $25.8 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $4.73 Million - $5.24 Million	-82,300 Reduced 19.67%	336,100 $20.1 Million
Q2 2020 Aug 13, 2020	BUY	$54.82 - $64.09 $6.52 Million - $7.63 Million	119,000 Added 39.75%	418,400 $24.2 Million
Q1 2020 May 11, 2020	SELL	$46.4 - $67.43 $8.06 Million - $11.7 Million	-173,700 Reduced 36.72%	299,400 $16.3 Million
Q4 2019 Feb 12, 2020	BUY	$49.21 - $64.19 $12 Million - $15.7 Million	244,000 Added 106.5%	473,100 $30.2 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $2.17 Million - $2.57 Million	50,700 Added 28.42%	229,100 $11.5 Million
Q2 2019 Aug 20, 2019	SELL	$44.62 - $49.34 $30.3 Million - $33.5 Million	-678,100 Reduced 79.17%	178,400 $8.09 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $22.5 Million - $26.8 Million	498,200 Added 139.05%	856,500 $40.9 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $7.77 Million - $10.1 Million	159,300 Added 80.05%	358,300 $18.3 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $3.09 Million - $3.48 Million	-55,900 Reduced 21.93%	199,000 $12.4 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $2.89 Million - $3.32 Million	-48,200 Reduced 15.9%	254,900 $16.1 Million
Q4 2017 Feb 14, 2018	SELL	$59.94 - $65.35 $3.78 Million - $4.12 Million	-63,000 Reduced 17.21%	303,100 $18.6 Million
Q3 2017 Nov 15, 2017	BUY	$55.23 - $63.74 $20.2 Million - $23.3 Million	366,100	366,100 $23.3 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$11.1 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.34 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.47 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.59 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.59 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account